Table of Contents Table of Contents
Previous Page  102 / 812 Next Page
Information
Show Menu
Previous Page 102 / 812 Next Page
Page Background

S98

24th European Congress of Psychiatry / European Psychiatry 33S (2016) S72–S115

Conclusions

Deficits in recognition of specific facial emotions

may reflect severity of psychiatric symptoms. They may be related

to specific clusters of psychotic symptoms, which need to be con-

firmed in further studies.

Disclosure of interest

The authors have not supplied their decla-

ration of competing interest.

http://dx.doi.org/10.1016/j.eurpsy.2016.01.066

FC63

Differential serum acute-phase

biomarker profile in schizophrenia

and bipolar disorder

B. Arranz

1 ,

, M. Sanchez

2

, M. Garriga

3

, G. Safont

2

,

P. Garcia-Portilla

4

, P. Sierra

5

, L. San

1

1

Parc Sanitari Sant Joan de Deu, CIBERSAM, CSMA Cornella,

Barcelona, Spain

2

Hospital Mutua Terrassa, Department of Psychiatry, Terrassa, Spain

3

Hospital Clinic, Department of Psychiatry, Barcelona, Spain

4

University of Oviedo, CIBERSAM, Area de Psiquiatría, Oviedo, Spain

5

Universidad de Valencia, Department of Psychiatry, Valencia, Spain

Corresponding author.

There is a growing interest in inflammation and immune dys-

function in severe psychiatric disorders such as schizophrenia and

bipolar disorder. This dysfunction seems to consist in abnormal

blood levels of cytokines and acute-phase proteins, with increased

levels of C-reactive protein (CRP), fibrinogen, homocysteine and

erythrocyte sedimentation rate (ESR). Higher levels can be found

in acute episodes and in patients with a higher cardiovascular risk.

Acute-phase protein serum parameters were determined in a

sample of 100 outpatients with schizophrenia (

n

= 50) or bipolar

disorder (

n

= 50) so as to assess differences in pro-inflammatory

state. Metabolic state was assessed through BMI, waist circumfer-

ence, glucose, cholesterol and triglyceride levels.

The whole sample showed higher levels of fibrinogen (mean

4

±

0.9 g/L), triglycerids (mean 2.9

±

8.5mmol/L), cholesterol-

LDL (mean 3

±

0.9mmol/L),

and homocysteine (mean

16.2

±

7.3 umol/L) than our laboratory reference values from

healthy individuals.

After correcting for gender and pharmacological treatment,

patients with schizophrenia showed higher levels of ESR, fibrino-

gen, glucose and CRP, while homocysteine was not statistically

different between patients with schizophrenia or bipolar disorder

(see

Table 1 ).

These results may suggest a different biomarker profile in

bipolar and schizophrenic outpatients, with a more severe pro-

inflammatory state in schizophrenia. Serum homocysteine levels

could be a state marker in both disorders.

Table 1

ESR (mm) Fibrinogen

(g/L)

Glucose

(mmol/L)

CRP (mg/L) Homocysteine

(mmol/L)

Schizophrenia

6

±

5.7 4.1

±

0.85 5.7

±

2.0

5.4

±

4.2 17.1

±

8.6

Bipolar disorder 3.1

±

2.2

*

3.6

±

0.76

*

4.4

±

0.95

*

2.2

±

2.0

*

15.9

±

5.7 (NS)

NS: not significant.

*

P

<0.05.

Disclosure of interest

The authors have not supplied their decla-

ration of competing interest.

http://dx.doi.org/10.1016/j.eurpsy.2016.01.067

FC64

Akathisia: Prevalence and risk factors

in a community-dwelling sample of

patients with schizophrenia. Results

from the multi-center FACE-SZ

Dataset

F. Berna

1 ,

, D. Misdrahi

2

, L. Boyer

3

, P.M. Llorca

4

, G. Fond

5

,

W.G. Face-sz

5

1

Hôpitaux Universitaires de Strasbourg, Inserm U1114, FMTS,

Fondation FondaMental, Psychiatry, Strasbourg cedex, France

2

Centre Hospitalier Charles-Perrens Bordeaux, CNRS UMR 5287,

INCIA, Fondation FondaMental, Psychiatry, Bordeaux, France

3

CHU Sainte-Marguerite, Pôle Psychiatrie Universitaire, Marseille,

France

4

CHU de Clermont-Ferrand, Fondation FondaMental, Psychiatry,

Clermont-Ferrand, France

5

Université Paris-Est, Inserm U955 eq15, GHU Mondor, DHU Pe-psy,

Psychiatry, Créteil, France

Corresponding author.

The main objective of this study was to determine the preva-

lence of akathisia in a community-dwelling sample of patients

with schizophrenia, and to determine the effects of treatments and

the clinical variables associated with akathisia. Three hundred and

seventy-two patients with schizophrenia or schizoaffective disor-

der were systematically included in the network of FondaMental

Expert Center for Schizophrenia and assessedwith validated scales.

Akathisia was measured with the Barnes Akathisia Scale (BAS).

Ongoing psychotropic treatment was recorded. The global preva-

lence of akathisia (as defined by a score of 2 or more on the

global akathisia subscale of the BAS) in our sample was 18.5%.

Patients who received antipsychotic polytherapy were at higher

risk of akathisia and this result remained significant (adjusted

odd ratio = 2.04,

P

= .025) after controlling the influence of age,

gender, level of education, level of psychotic symptoms, sub-

stance use comorbidities, current administration of antidepressant,

anticholinergic drugs, benzodiazepines, and daily-administered

antipsychotic dose. Our results indicate that antipsychotic poly-

therapy should be at best avoided and suggest that monotherapy

should be recommended in cases of akathisia. Long-term adminis-

tration of benzodiazepines or anticholinergic drugs does not seem

to be advisable in cases of akathisia, given the potential side effects

of these medications.

Disclosure of interest

The authors have not supplied their decla-

ration of competing interest.

http://dx.doi.org/10.1016/j.eurpsy.2016.01.068

FC65

Antipsychotic-induced tardive

dyskinesia: The role of glutamatergic

system

A. Boiko

1 ,

, S. Ivanova

1

, A. Semke

2

1

Mental Health Research Institute SB RAMSci, Laboratory of

Molecular Genetics and Biochemistry, Tomsk, Russia

2

Mental Health Research Institute SB RAMSci, Department of Clinical

Psychiatry, Tomsk, Russia

Corresponding author.

Tardive dyskinesia (TD) occurs in 20–25% of patients with

long-term antipsychotic therapy. Abnormalities in glutamatergic

transmission are considered one of the key components of the

pathogenesis of drug-induced side effects. Glutamate acts as exci-

totoxin under certain conditions and in excessive concentrations.

Aim is to study the concentration of glutamate and analysis of sin-

gle nucleotide polymorphisms (SNP) in genes coding the glutamate

transporter andNMDA-receptors in schizophrenic patientswith TD

and without it.